PEXA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.038 EUR | +12.43% |
|
+22.58% | +2.70% |
| 05-15 | PExA AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-21 | PExA AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2021 | 2.16M 205K 189K 280K | Sales 2022 | 6.03M 573K 528K 781K | Capitalization | 27.23M 2.59M 2.38M 3.53M |
|---|---|---|---|---|---|
| Net income 2021 | -7M -665K -613K -907K | Net income 2022 | -4M -380K -350K -518K | EV / Sales 2021 | 13.5 x |
| Net cash position 2021 | 20.72M 1.97M 1.81M 2.68M | Net cash position 2022 | 18.25M 1.73M 1.6M 2.36M | EV / Sales 2022 | 1.49 x |
| P/E ratio 2021 |
-4.95
x | P/E ratio 2022 |
-5.73
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | +12.43% | ||
| 1 week | +22.58% | ||
| 1 month | +32.87% | ||
| 3 months | +11.76% | ||
| 6 months | -1.04% | ||
| Current year | +2.70% |
1 week
0.03
0.04
1 month
0.030.04
Current year
0.030.05
1 year
0.030.05
3 years
0.030.05
5 years
0.030.05
10 years
0.030.05
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | - | |
Jörgen Östling
CTO | Chief Tech/Sci/R&D Officer | - | - |
Svante Höjer
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 17-12-31 | |
| Director/Board Member | 71 | 20-12-31 | |
| Chairman | 70 | 11-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.038 | +12.43% |
| 24-05-30 | 0.0338 | +7.64% |
| 24-05-29 | 0.0314 | -5.99% |
| 24-05-28 | 0.0334 | +2.45% |
| 24-05-27 | 0.0326 | +5.16% |
Delayed Quote Deutsche Boerse AG, May 31, 2024 at 09:29 am
More quotes
PExA AB is a Sweden-based company engaged in the advanced equipment and technology industry. The Company develops, manufactures and markets a non-invasive research instrument to study respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The instrument provides lung researchers with a non-invasive method for collecting microscopic particles, potential biomarkers for diseases, from small airways in exhaled air to diagnose, monitor and provide treatment of respiratory diseases.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -27.52% | 16.33B | |
| -40.04% | 2.96B | |
| +15.16% | 1.82B | |
| -6.86% | 1.55B | |
| +38.67% | 1.41B | |
| -15.36% | 976M | |
| -26.08% | 846M | |
| +3.53% | 811M | |
| -24.63% | 631M |
- Stock Market
- Equities
- PEXA B Stock
- FA0 Stock
